Show Health and Fitness Publications

Wed, December 14, 2011

[ Wed, Dec 14th 2011 ]: Market Wire

Pfizer, Cisco, Walt Disney, Research In Motion, U .. ban Outfitters and Green Mountain Coffee Roasters

[ Wed, Dec 14th 2011 ]: Market Wire

A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)

[ Wed, Dec 14th 2011 ]: Market Wire

St. Jude Medical annuncia il primo impianto nella .. clinica per la valutazione dalla valvola cardiac

[ Wed, Dec 14th 2011 ]: Market Wire

CytoSorbents Awarded US Army SBIR Trauma Grant

[ Wed, Dec 14th 2011 ]: Market Wire

IntegraMed America Selects Adaptive Planning

[ Wed, Dec 14th 2011 ]: Market Wire

Definitieve fase 2 gegevens van evaluatie REVLIMI .. et recidiverende of refractaire chronische lymfat

[ Wed, Dec 14th 2011 ]: Market Wire

Datos finales de la Fase II que evalan REVLIMID y .. eucemia linfoctica crnica recurrente o resistente

[ Wed, Dec 14th 2011 ]: Market Wire

Premiere Cooperative Group in Adult Lymphoma Rese .. for Study in Second Most Common Lymphoma Subtype

[ Wed, Dec 14th 2011 ]: Market Wire

Salix Pharmaceuticals Announces NDA Submission fo .. emer for the Treatment of HIV-Associated Diarrhea

[ Wed, Dec 14th 2011 ]: Market Wire

Meta-analysis of Five Clinical Trials including C .. T Study Published in American Journal of Obstetri

[ Wed, Dec 14th 2011 ]: Market Wire

REVLIMID evaluado en combinacin con rituximab com .. pacientes con leucemia linfoctica crnica no trata

[ Wed, Dec 14th 2011 ]: Market Wire

Presentados en ASH los datos de un estudio de Fas .. en pacientes con mieloma indolente de alto riesgo

[ Wed, Dec 14th 2011 ]: Market Wire

OncoSec Medical Engages The Investor Relations Group

[ Wed, Dec 14th 2011 ]: Market Wire

Rsultats dfinitifs de laessai de phase II valuant .. ez les patients atteints de leucmie lymphocytaire

[ Wed, Dec 14th 2011 ]: Market Wire

Threshold Pharmaceuticals Announces Promising Pha .. Trial Results in Patients With Advanced Leukemias

[ Wed, Dec 14th 2011 ]: Market Wire

REVLIMID a t valu en combinaison avec le Rituxima .. ntiel destin aux patients atteints de leucmie lym

Tue, December 13, 2011

[ Tue, Dec 13th 2011 ]: Market Wire

Bio-Path Holdingsa Initial Phase I Data in Leukem .. s That Its Neutral Lipid Delivery Technology Anti

[ Tue, Dec 13th 2011 ]: Market Wire

GenVec President and Chief Executive Officer Announces Retirement

[ Tue, Dec 13th 2011 ]: Market Wire

China Botanic Announces Development of New Siberian Ginseng Polysaccharide Extract Powder

[ Tue, Dec 13th 2011 ]: Market Wire

Endgltige Daten aus multizentrischer Phase-II-Stu .. binationstherapie von VIDAZA und REVLIMID fr MDS-

[ Tue, Dec 13th 2011 ]: Market Wire

Stem Cell Therapeutics Announces Additions to Advisory Board

[ Tue, Dec 13th 2011 ]: Market Wire

Eindgegevens van Fase II multi-center onderzoek n .. REVLIMID bij patinten met hoogrisico MDS gepresen

[ Tue, Dec 13th 2011 ]: Market Wire

Synergy Pharmaceuticals, Inc. reicht Klage ein ge .. Inc. und dessen Chief Scientific Officer und Sen

[ Tue, Dec 13th 2011 ]: Market Wire

Prsentation laASH des rsultats dfinitifs daune tu .. I valuant la combinaison de VIDAZA et de REVLIMID

[ Tue, Dec 13th 2011 ]: Market Wire

Une tude de phase III avec traitement continu de .. ion statistiquement considrable de la survie sans

[ Tue, Dec 13th 2011 ]: Market Wire

Threshold Pharmaceuticals Announces Update to TH- .. resented at the Oppenheimer Healthcare Conference

[ Tue, Dec 13th 2011 ]: Market Wire

NTRR Targets $390 Billion Weight Loss and Diet Management Market

[ Tue, Dec 13th 2011 ]: Market Wire

FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVEa"

[ Tue, Dec 13th 2011 ]: Market Wire

Radient Pharmaceuticals Launches New Onko-Sure Website, Facebook and Twitter Outreach

[ Tue, Dec 13th 2011 ]: Market Wire

Une tude de dosage value REVLIMID chez des patien .. aits, atteints de leucmie lymphocytaire chronique

[ Tue, Dec 13th 2011 ]: Market Wire

Les rsultats d'une analyse comparative rvlent que .. tistiquement significative le risque de dcs, sans

[ Tue, Dec 13th 2011 ]: Market Wire

Synergy Pharmaceuticals, Inc. dpose plainte contr .. Inc. et son conseiller scientifique en chef et VP

[ Tue, Dec 13th 2011 ]: Market Wire

Synergy Pharmaceuticals, Inc. Files Suit Against .. c. and its Chief Scientific Officer and Senior VP

[ Tue, Dec 13th 2011 ]: Market Wire

Synergy Pharmaceuticals, Inc. fa causa ad Ironwoo .. suo Direttore Scientifico e Vicepresidente Senior

[ Tue, Dec 13th 2011 ]: Market Wire

Synergy Pharmaceuticals, Inc. spant geding aan te .. , Inc. en haar Chief Scientific Officer en Senior

Mon, December 12, 2011

[ Mon, Dec 12th 2011 ]: Market Wire

Abiomed 2011 Investor Day Webcast Replay Available

[ Mon, Dec 12th 2011 ]: Market Wire

First FDA-Approved Treatment for Myelofibrosis, J .. ssed in Multiple Presentations at 2011 ASH Annual

[ Mon, Dec 12th 2011 ]: Market Wire

Paladin Labs Announces the Canadian Launch of DigiFab(TM) Digoxin Immune Fab (Ovine)

[ Mon, Dec 12th 2011 ]: Market Wire

Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting

[ Mon, Dec 12th 2011 ]: Market Wire

Community Health Systems Announces Definitive Agreement to Acquire Blue Island, Illinois Hospital

[ Mon, Dec 12th 2011 ]: Market Wire

AMAG Pharmaceuticals Announces Preliminary Data R .. acy of a Single Infusion of 1020 mg Ferumoxytol (

[ Mon, Dec 12th 2011 ]: Market Wire

Nektar Therapeutics Initiates Phase 3 BEACON Tria .. f NKTR-102 in Women with Metastatic Breast Cancer

[ Mon, Dec 12th 2011 ]: Market Wire

ProMetic Announces Achievement of Significant Targeted Milestone With a Multinational Company

[ Mon, Dec 12th 2011 ]: Market Wire

PDL BioPharma Announces Departure of Chief Financial Officer

[ Mon, Dec 12th 2011 ]: Market Wire

Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer

[ Mon, Dec 12th 2011 ]: Market Wire

Mylan Names John Thievon President of Dey Pharma

[ Mon, Dec 12th 2011 ]: Market Wire

Soligenix Announces Publication of Results of its .. al Trial of orBec in the Prevention of Acute GVHD

[ Mon, Dec 12th 2011 ]: Market Wire

MELA Sciences Announces Additions to Board of Directors

[ Mon, Dec 12th 2011 ]: Market Wire

Emergent BioSolutions to Participate in January 2012 Investor Conferences

[ Mon, Dec 12th 2011 ]: Market Wire

PDL BioPharma Corrects Its Adjusted Conversion Rates for Its Convertible Notes

[ Mon, Dec 12th 2011 ]: Market Wire

Kraig Biocraft Laboratories Receives New Custom Z .. er Configurations for Advanced Fibers Development

[ Mon, Dec 12th 2011 ]: Market Wire

Abbott and Reata Pharmaceuticals Announce Agreeme .. ze Next-Generation Antioxidant Inflammation Modul

[ Mon, Dec 12th 2011 ]: Market Wire

10-Year Study Demonstrates IRIDEX MicroPulsea" La .. ffective for Patients with Diabetic Macular Edema

[ Mon, Dec 12th 2011 ]: Market Wire

Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference

Sun, December 11, 2011

[ Sun, Dec 11th 2011 ]: Market Wire

Pharming granted U.S. patent on C1 inhibitor use in ischemia reperfusion injury indications

[ Sun, Dec 11th 2011 ]: Market Wire

Onyx Pharmaceuticals Announces FDA Standard Revie .. New Drug Application for the Treatment of Relapse

Sat, December 10, 2011

[ Sat, Dec 10th 2011 ]: Market Wire

Onyx Pharmaceuticals Provides Update on Carfilzom .. 3rd American Society of Hematology Annual Meeting

[ Sat, Dec 10th 2011 ]: Market Wire

Brower Piven Encourages Investors Who Have Losses .. nvestment in Pain Therapeutics, Inc. to Inquire A

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead annuncia i dati raccolti in due anni nella .. le di Fase III su elvitegravir,;;;

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead annuncia i dati raccolti in due anni nella .. le di Fase III su elvitegravir,;;;

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead annuncia i dati raccolti in due anni nella .. le di Fase III su elvitegravir,;;;

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead annuncia i dati raccolti in due anni nella .. le di Fase III su elvitegravir,;;; u

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead annuncia i dati raccolti in due anni nella .. le di Fase III su elvitegravir,;;;

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead annuncia i dati raccolti in due anni nella .. le di Fase III su elvitegravir,;;;

[ Sat, Dec 10th 2011 ]: Market Wire

Abiomed Announces Expanded Heart Recovery Strategy with Multi Year Growth Initiatives

[ Sat, Dec 10th 2011 ]: Market Wire

Exact Sciences Announces Successful Completion of Public Offering of Common Stock

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead maakt tweejaarsgegevens bekend van crucial .. ie van elvitegravir, een integraseremmer voor hiv

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead gibt Zweijahresdaten der Phase-3-Pivotstud .. itegravir, einem Integrasehemmer bei HIV, bekannt

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead annuncia i dati raccolti in due anni nella .. le di Fase III su elvitegravir, un inibitore dell

[ Sat, Dec 10th 2011 ]: Market Wire

Data Shows Medtronic AdaptiveStima" with RestoreSensora" Provides Pain Relief and Convenience

[ Sat, Dec 10th 2011 ]: Market Wire

Gilead Announces Two-Year Data From Pivotal Phase .. y of Elvitegravir, an Integrase Inhibitor for HIV

Fri, December 9, 2011